Inflammatory bowel disease (IBD) is a kind of chronic inflammatory immune disease of the intestine. In recent years, biologics and small molecule agents with different targets have been used for the treatment of IBD. However, it also brings concerns about opportunistic infections, among which the reactivation of latent tuberculosis infection is more harmful. China is still one of the epidemic areas of tuberculosis, and clinicians attach great importance to the reactivation of latent tuberculosis infection induced by biologics and small molecule agents. This paper reviews the risk of latent tuberculosis infection reactivation associated with biologics and small molecule agents and the recommendation of the guideline. It is expected to provide a reference for the application of these medications in patients with inflammatory bowel disease complicated by latent tuberculosis infection.

Inflammatory bowel disease (IBD) is a kind of chronic inflammatory immune disease of the intestine. In recent years, biologics and small molecule agents with different targets have been used for the treatment of IBD. However, it also brings concerns about opportunistic infections, among which the reactivation of latent tuberculosis infection is more harmful. China is still one of the epidemic areas of tuberculosis, and clinicians attach great importance to the reactivation of latent tuberculosis infection induced by biologics and small molecule agents. This paper reviews the risk of latent tuberculosis infection reactivation associated with biologics and small molecule agents and the recommendation of the guideline. It is expected to provide a reference for the application of these medications in patients with inflammatory bowel disease complicated by latent tuberculosis infection.